1 min read
The Stock Exchange of Hong Kong Limited (the Exchange) recently announced significant reforms to attract high-growth innovative companies to list in Hong Kong. One of the most eye-catching reforms is the introduction of a new chapter (the Biotech Chapter) to the Main Board Listing Rules (the Listing Rules) to allow the listing of biotech companies that are pre-revenue. On 23 February 2018, the Exchange released a new consultation paper seeking comments on the proposed amendments to the Listing Rules relating to the Biotech Chapter.
In this Client Briefing, we provide an overview of the listing criteria under the Biotech Chapter issued by the Exchange and what an applicant applying for a listing must demonstrate.
How we can assist
If you have any queries or require assistance regarding the listing criteria, please contact any of the team members below or your usual contact at Slaughter and May.
2018年2月|简报
香港联合交易所（“联交所”）最近宣布进行重大改革，以吸引高增长的创新型公司在香港上市。最引人瞩目的改革之一是在《主板上市规则》（“《上市规则》”）中新增一个章节（“《生物科技章节》”），允许未有收入的生物科技公司来香港上市。联交所于2018年2月23日发表新谘询文件，征求公众对联交所提议的《生物科技章节》的意见。
在本客户简报中，我们介绍联交所发表的《生物科技章节》项下的上市标准及公司在申请上市时必须满足的事项。
我们提供的协助
如阁下对上市标准有任何疑问或需要协助，请与以下团队成员或阁下惯常联络的司力达律师事务所的人员联系，我们定当竭诚为阁下提供协助。